Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Cash (2020 - 2025)

RxSight's Change in Cash history spans 6 years, with the latest figure at -$9.7 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 40445.83% year-over-year to -$9.7 million; the TTM value through Dec 2025 reached $3.2 million, down 54.02%, while the annual FY2025 figure was $3.2 million, 54.02% down from the prior year.
  • Change in Cash reached -$9.7 million in Q4 2025 per RXST's latest filing, up from -$10.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $26.5 million in Q3 2021 to a low of -$43.7 million in Q4 2021.
  • Average Change in Cash over 5 years is $312200.0, with a median of -$147000.0 recorded in 2022.
  • Peak YoY movement for Change in Cash: soared 5409.4% in 2021, then tumbled 40445.83% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$43.7 million in 2021, then skyrocketed by 106.58% to $2.9 million in 2022, then crashed by 105.78% to -$166000.0 in 2023, then skyrocketed by 114.46% to $24000.0 in 2024, then crashed by 40445.83% to -$9.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Change in Cash are -$9.7 million (Q4 2025), -$10.7 million (Q3 2025), and $12.4 million (Q2 2025).